1VPa

1VPa is a novel psychoactive substance that has emerged in the designer drug market. Its chemical name is 1-(5-fluoropentyl)-N-propyl-1H-indazole-3-carboxamide. As a synthetic cannabinoid, it is structurally related to other compounds like AB-FUBINACA and ADB-FUBINACA, which are known to act as agonists at cannabinoid receptors in the brain. The intended effects of 1VPa are typically sought for their psychoactive properties, which can include euphoria, relaxation, and altered perception.

Information regarding the pharmacology and toxicology of 1VPa is limited due to its recent appearance and the lack of extensive scientific research. Studies on its metabolism, long-term effects, and potential for harm are scarce. Users may experience a range of adverse effects, similar to other synthetic cannabinoids, which can include anxiety, paranoia, rapid heart rate, nausea, and in severe cases, more serious cardiovascular or psychiatric issues. The potency and precise mechanism of action of 1VPa are not well-established.

The legal status of 1VPa varies internationally, with many countries implementing controls on novel psychoactive substances as they emerge. Its availability is generally through online vendors or clandestine laboratories. Due to the lack of quality control and the unknown risks associated with its use, 1VPa is considered a substance of concern by public health authorities. Further research is needed to fully understand its properties and potential dangers.